Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Hyperglycemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma 2Leukemia 2Leukemia, Myeloid, Acute 1Insulin Resistance 1Hyperphagia 1Diabetes Mellitus, Type 2 1Congenital Abnormalities 1Burkitt Lymphoma 1

Interventions

Cytarabine 358Cyclophosphamide 241Azacitidine 213fludarabine phosphate 199venetoclax 198fludarabine 196Busulfan 148Decitabine 132Mycophenolic Acid 123Whole-Body Irradiation 122Peripheral Blood Stem Cell Transplantation 118Tacrolimus 115Granulocyte Colony-Stimulating Factor 104Idarubicin 100Filgrastim 100Melphalan 89Cyclosporine 89Methotrexate 83Daunorubicin 76Antilymphocyte Serum 75Etoposide 73Mitoxantrone 67Clofarabine 67Gemtuzumab 59Stem Cell Transplantation 55Thiotepa 51Cladribine 46Injections 45Specimen Handling 44thymoglobulin 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Myeloid, Acute × Insulin Glargine × Clear all
NCT00943709 2013-08-30

Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia

Rutgers, The State University of New Jersey

Phase 3 Withdrawn
LymphoidOther hematologic neoplasm

Congenital Abnormalities, Hyperglycemia, Leukemia, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡